Markets
BSE See NSE See 27,782.25
-53.66 (-0.19%)

Aurobindo Pharma Gets USFDA Approval For Generic Diovan HCT

By Shrikant Akolkar | 3/22/2013 3:42 PM Friday

Aurobindo Pharma has reported receiving final approval for the Valsartan and Hydrochlorothiazide tablets (brand name Diovan HCT held by Novartis). The drug is indicated in the treatment of hypertension to lower blood pressure. The market size of this drug is USD 1.7 billion (Rs 9350 crore) as per the company’s BSE filings. Aurobindo has said that the product is ready for launch and that this will happen soon.

Drug major Mylan has already launched an authorised generic version of this drug in USA. We believe that Aurobindo is the first to launch the generic of this drug considering that Mylan’s was an authorised generic.

We spoke to the company spokesperson, who declined to comment on the pricing and market share of the drug. However, he did say that the company expects to see about 3-4 generic players in the market. Considering this, about 20% market share looks achievable for Aurobindo. Since it is the first to launch, there would not be a massive erosion of price initially. However, as the drug has already fallen out of patent cover, new players would try to enter the market as faster as possible. Once other companies start launching their versions of the drug, the price will go down.

Considering 80% price erosion and 10% market share for Aurobindo, it can be estimated that the company may achieve revenues of about Rs 700 crore from the drug. Of course, these numbers are based on the assumption that the company makes the best of this opportunity.

With this approval, Aurobindo Pharma has a total of 181 ANDA approvals from USFDA, of which 156 are final and 25 are tentative approvals.

Find More Articles on: Markets, DSIJ Mindshare, Product, Large Cap

collapse Related Readings collapse

DSIJ
Mindshare

Overnight Digest – Stocks to look out for on August 29

Overnight Digest – Stocks to look out for on August 29

The stocks which could witness a significant movement on August 29 are Capital Trust, Trident, IOC, Alankit and DLF.

Welspun's loss becomes Trident gain

Welspun's loss becomes Trident gain

‘One man’s trash another man’s treasure' is an idiom that somewhat resembles the situation in which Trident is right know sailing. The BSE 500 stock on Aug 26 has emerged as the top gainer on the bourses surging by more than 10 per cent. 

Indices struggled; Tata Motors surges

Indices struggled; Tata Motors surges

The bears have been active from last three consecutive days and the Indian markets are struggling to breakout. In first day of F&O trade, Banking, Healthcare, IT and Capital Goods indices closed on a negative note. The Nifty ended lower by 19 points at 8572; and Sensex was 53 points down at 27782. The indices lost -0.31 to -0.19 per cent respectively.

Tata Motors ends in green despite of weak Q1FY17

Tata Motors ends in green despite of weak Q1FY17

Tata Motors has declared its Q1FY17 results on Friday. The company’s revenue has increased by 9.02 per cent to Rs 67056 crore in Q1FY17 as compared to same period in previous fiscal.

Mid-market commentary Aug 26

Mid-market commentary Aug 26

Indian markets opened on a positive note but retreated from the very moment to trade in red, continuing with its previous fall. Markets have seen gradual lower tops and lower bottoms in the intraday trade. Broader markets are flat.

Abbott India witnesses incremental revenue in Q1FY17

Abbott India witnesses incremental revenue in Q1FY17

Abbott India has declared its Q1FY17 results on Friday. The company’s revenue has increased by 15.83 per cent to Rs 738 crore in Q1FY17 as compared to same period in previous fiscal. 

Top Gainers and Losers of mid-day

Top Gainers and Losers of mid-day

Following are the top gainers and losers list of Aug 26 as on 12.00 pm.  Trident and ICRA are up by double digits’ gainers. Trident has largely rallied on the news that Target Corp is considering to give order of bed sheets to Trident, were as Jaypee Infratech is the largest loser for the day. 

Medicate your portfolio with Pharma stocks

Medicate your portfolio with Pharma stocks

Pharmaceutical industry is a knowledge intensive industry, and faces its own share of challenges.  India is a leading and most favoured supplier of formulations to advanced markets such as US, Europe and semi regulated markets like Africa, LATAM (Latin America).

Doom's day set for 7 PSUs by Centre

Doom's day set for 7 PSUs by Centre

In its privatisation initiative and acting on the NITI Aayog recommendation, the Government of India is all set to seek the cabinet's approval for shutting down selected seven state owned companies.

Reliance Jio's launch to create ripples in the telecom industry

Reliance Jio's launch to create ripples in the telecom industry

Investors as well as the whole telecom industry is keeping a close eye on the customer acquisition strategy that Reliance Jio may adopt, as it is widely expected that Reliance Jio for acquiring new customers will be offering freebies. The rivals naturally will be strategising to retain their customers by slashing tariff rates. State run BSNL is also expected to be hit by the Jio launch.

Subscribe to
Newsletter

news letter

More for the early bird.

Get the post-market reports and breakfast news right in your inbox. See latest »

Market
CHIT CHAT

What is your view on markets today?

200  Characters Remaining.
Please LOGIN  to post your comments or Click here to go back.
sachin koshti Aug 26 06:53PM
what are trading timing
arjun kamathe Aug 26 03:23PM
market flat today
somnath bhosale Aug 26 02:42PM
and SBIN
somnath bhosale Aug 26 02:42PM
buy tata steel
VIKRAM NAIK Aug 26 02:26PM
Trigger price not executed